Simon Plyte
Chief Scientific Officer Biomunex Pharmaceuticals
Seminars
Thursday 9th July 2026
MAIT Engagers: A Safer Modality with Large Therapeutic Window for the Treatment of Cancer
3:00 pm
- Novelty: Leverage a highly abundant, underexplored T-cell population to expand the therapeutic window and enable safer immune engagement strategies
- Activity in solid tumour: MAIT engagers avoid Treg activation in solid tumours, preventing immune suppression seen with conventional CD3 engagers
- Safety: MAIT engagers uniquely activate MAIT cells and do not cause cytokine release syndrome, at difference to CD3 engagers
